Proteasome Inhibitor

Overview

Proteasomes are small, barrel shaped structures that are found in all cells. They play an important role in maintaining a healthy cell environment by removing ineffective proteins. This is important because cancerous plasma cells produce large amounts of ineffective proteins.

A proteasome inhibitor temporarily stops (or inhibits) the proteasomes from doing their job. This allows the ineffective proteins to build up inside of the cancer cell until it ultimately destroys itself.

There are several proteasome inhibitors that are approved for use in multiple myeloma. This classification of drug is currently given in one of three ways - as an IV infusion, as a shot in the abdominal area or as an oral pill.

Explore Tags

Myeloma Treatments

The following is a listing of myeloma treatments associated with this tag.

Untreated / Newly Diagnosed Multiple Myeloma

The following is a listing of treatments in development for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.

Early Relapse Multiple Myeloma

The following is a listing of treatments in development for patients with multiple myeloma who have received one to two prior lines of therapy.

Late Relapse Multiple Myeloma

The following is a listing of treatments in development for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma

The following is a listing of treatments in development for patients with Smoldering Myeloma.

Myeloma Clinical Trials

The following is a listing of myeloma clinical trials associated with this tag.

All Clinical Trials

View all active clinical trials around the US.

SparkCures Verified Accurate, up-to-date information. Learn more


Untreated / Newly Diagnosed Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Resources